GlaxoSmithKline's malaria vaccine RTS,S cut the number of malaria cases by around 25% in infants and nearly 50% in young children after 18 months of follow-up in a clinical trial involving almost 15,500 children in seven African countries. The findings are a step up from previous trial results showing that the vaccine may provide only modest protection at a limited amount of time. "Based on these data, GSK now intends to submit, in 2014, a regulatory application to the European Medicines Agency (EMA)," according to the company, which is developing the drug with the PATH Malaria Vaccine Initiative.

Full Story:

Related Summaries